Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis

Pediatric Cardiology

Volumn 36, Issue 7, 2015, Pages 1442-1451

  Ramakrishnan, Anushuya ^a   Lee, Laura J ^a   Mitchell, Laura E ^a   Agopian, A J ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Congenital heart defects; Hypertension; Meta analysis; Pregnancy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT;

ARTICLE; ATRIOVENTRICULAR SEPTAL DEFECT; CONGENITAL HEART MALFORMATION; DRUG EXPOSURE; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE SEPTUM DEFECT; HETEROTAXY SYNDROME; HUMAN; MATERNAL HYPERTENSION; PREGNANT WOMAN; PROGENY; RISK ASSESSMENT; RISK FACTOR; SITUS INVERSUS; SYSTEMATIC REVIEW; FAMILY; FEMALE; HEART DEFECTS, CONGENITAL; HYPERTENSION; META ANALYSIS; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RISK;

ANTIHYPERTENSIVE AGENTS; FAMILY; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL EXPOSURE DELAYED EFFECTS; RISK;

EID: 84941944223     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-015-1182-9     Document Type: Article

References (41)

1. Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH (2014) Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens 32(3):454–463. doi:10.1097/HJH.0000000000000069
2. Alwan S, Polifka JE, Friedman JM (2005) Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A 73(2):123–130. doi:10.1002/bdra.20102
3. Ananth CV, Peedicayil A, Savitz DA (1995) Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births. Epidemiology 6(4):391–395
4. Banhidy F, Acs N, Puho EH, Czeizel AE (2011) Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertens Res 34(2):257–263. doi:10.1038/hr.2010.227
5. Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, Franklin JM, Mogun H, Hernandez-Diaz S (2014) Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol. doi:10.1016/j.ajog.2014.09.031
6. Botto LD, Correa A, Erickson JD (2001) Racial and temporal variations in the prevalence of heart defects. Pediatrics 107(3):E32
7. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, National Birth Defects Prevention Study (2007) Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A 79(10):714–727. doi:10.1002/bdra.20403
8. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt LA, Romitti PA, Mitchell AA, Olney RS, Correa A, National Birth Defects Prevention Study (2009) Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 54(1):63–70. doi:10.1161/HYPERTENSIONAHA.109.129098
9. CDC (1997) Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada and Isreal, 1987–1995. MMWR Morb Mortal Wkly Rep 46:2
10. Clark EB (1986) Mechanisms in the pathogenesis of congenital cardiac malformations. In: Pierpont ME, Moller JH (eds) The genetics of cardiovascular disease. Martinus Nijhoff Publishing, Boston, MA, p 8
11. Clark EB (1996) Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Semin Perinatol 20(6):465–472
12. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354(23):2443–2451. doi:10.1056/NEJMoa055202
13. Czeizel AE, Banhidy F (2011) Chronic hypertension in pregnancy. Curr Opin Obstet Gynecol 23(2):76–81. doi:10.1097/GCO.0b013e328342b7a9
14. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Dublin S, Platt R (2011) Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 20(2):138–145. doi:10.1002/pds.2068
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
16. Excellence NIfHaC (2010) Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. NICE Guidelines. Accessed June 9, 2014
17. Fang J, Madhavan S, Alderman MH (1999) The influence of maternal hypertension on low birth weight: differences among ethnic populations. Ethn Dis 9(3):369–376
18. Ferencz C, Rubin J, Loffredo C, Magee C (1993) Epidemiology of Congenital Heart Disease: the Baltimore Washington Infant Study 1981–89. Futura Publishing Company, Mount Kisco
19. Hoffman JI (1990) Congenital heart disease: incidence and inheritance. Pediatr Clin North Am 37(1):25–43
20. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL, American Heart Association Council on Cardiovascular Disease in the Young (2007) Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115(23):2995–3014. doi:10.1161/CIRCULATIONAHA.106.183216
21. Johnson KC, Rouleau J (1997) Temporal trends in Canadian birth defects birth prevalences, 1979–1993. Can J Public Health 88(3):169–176
22. Kallen BA, Otterblad Olausson P (2003) Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17(3):255–261
23. Lawler J, Osman M, Shelton JA, Yeh J (2007) Population-based analysis of hypertensive disorders in pregnancy. Hypertens Pregnancy 26(1):67–76. doi:10.1080/10641950601147945
24. Lennestal R, Otterblad Olausson P, Kallen B (2009) Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 65(6):615–625. doi:10.1007/s00228-009-0620-0
25. Lennestal R, Olausson P, Kallen B (2009) Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in infants. Eur J Clin Phamacol 65:10
26. Li DK, Yang C, Andrade S, Tavares V, Ferber JR (2011) Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 343:d5931. doi:10.1136/bmj.d5931
27. Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, Kramer MS (2013) Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. Circulation 128(6):583–589. doi:10.1161/CIRCULATIONAHA.112.001054
28. Malm H, Artama M, Gissler M, Klaukka T, Merilainen J, Nylander O, Padlan M, Palva E, Ritvannen A, Tyrkko K (2008) First trimester use of ACE-inhibitors and risk of major malformations. Reprod Toxicol 05:5
29. Mastrobattista JM (1997) Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol 21(2):124–134
30. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. doi:10.1016/j.jclinepi.2009.06.005
31. Moussa HN, Arian SE, Sibai BM (2014) Management of hypertensive disorders in pregnancy. Women’s Health 10(4):385–404. doi:10.2217/whe.14.32
32. Nakhai-Pour HR, Rey E, Berard A (2010) Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B 89(2):147–154. doi:10.1002/bdrb.20238
33. Roberts CL, Bell JC, Ford JB, Hadfield RM, Algert CS, Morris JM (2008) The accuracy of reporting of the hypertensive disorders of pregnancy in population health data. Hypertens Pregnancy 27(3):285–297. doi:10.1080/10641950701826695
34. Roberts JMAP, Bakris G et al (2013) Hypertension in pregnancy report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol 122(5):9
35. Schoendorfer C, Hannemann D, Meister R, Eléfant E, Maarschalkerweerd B, Arnon J, Vial T, Pinilla E, Clementi M, Gnansia E, Santis M, MalmH Dolivo A, Schaefer C (2008) The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 26:24
36. Sorensen HT, Czeizel AE, Rockenbauer M, Steffensen FH, Olsen J (2001) The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand 80(5):397–401
37. Tikkanen J, Heinonen OP (1990) Risk factors for cardiovascular malformations in Finland. Eur J Epidemiol 6(4):348–356
38. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2013) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Mar 24, 2015
39. Vereczkey A, Kosa Z, Csaky-Szunyogh M, Gerencser B, Czeizel AE (2014) Birth outcomes of cases with conotruncal defects of heart—a population-based case–control study. J Maternal-Fetal Neonatal Med. doi:10.3109/14767058.2014.918598
40. Yang Q, Chen H, Correa A, Devine O, Mathews TJ, Honein MA (2006) Racial differences in infant mortality attributable to birth defects in the United States, 1989–2002. Birth Defects Res A 76(10):706–713. doi:10.1002/bdra.20308
41. Zen TD, Rosa RF, Zen PR, Trevisan P, da Silva AP, Ricachinevsky CP, Paskulin GA (2011) Gestational and family risk factors for carriers of congenital heart defects in southern Brazil. Pediatr Int 53(4):551–557. doi:10.1111/j.1442-200X.2011.03341.x